Literature DB >> 34505065

Complement activation promoted by the lectin pathway mediates C3aR-dependent sarcoma progression and immunosuppression.

Elena Magrini1, Sabrina Di Marco1, Sarah N Mapelli1, Chiara Perucchini1, Fabio Pasqualini2, Alessia Donato2, Maria de la Luz Guevara Lopez3, Roberta Carriero1, Andrea Ponzetta1, Piergiuseppe Colombo1, Ferdinando Cananzi1,2, Domenico Supino1,2, Edimara S Reis4, Clelia Peano1,5, Antonio Inforzato1,2, Sebastien Jaillon1,2, Andrea Doni1, John D Lambris4, Alberto Mantovani6,7,8, Cecilia Garlanda9,10.   

Abstract

Complement has emerged as a component of tumor promoting inflammation. We conducted a systematic assessment of the role of complement activation and effector pathways in sarcomas. C3 -/-, MBL1/2 -/- and C4 -/- mice showed reduced susceptibility to 3-methylcholanthrene sarcomagenesis and transplanted sarcomas, whereas C1q and factor B deficiency had marginal effects. Complement 3a receptor (C3aR), but not C5aR1 and C5aR2, deficiency mirrored the phenotype of C3 -/- mice. C3 and C3aR deficiency were associated with reduced accumulation and functional skewing of tumor-associated macrophages, increased T cell activation and response to anti-PD-1 therapy. Transcriptional profiling of sarcoma infiltrating macrophages and monocytes revealed the enrichment of MHC II-dependent antigen presentation pathway in C3-deficient cells. In patients, C3aR expression correlated with a macrophage population signature and C3 deficiency-associated signatures predicted better clinical outcome. These results suggest that the lectin pathway and C3a/C3aR axis are key components of complement and macrophage-mediated sarcoma promotion and immunosuppression.

Entities:  

Keywords:  C3; C3a receptor (C3aR); Complement; cancer; cancer-related inflammation; immunotherapy; lectin pathway; macrophages; mannose binding lectin (MBL); sarcoma

Mesh:

Substances:

Year:  2021        PMID: 34505065      PMCID: PMC8425276          DOI: 10.1038/s43018-021-00173-0

Source DB:  PubMed          Journal:  Nat Cancer        ISSN: 2662-1347


  53 in total

1.  CD20 levels determine the in vitro susceptibility to rituximab and complement of B-cell chronic lymphocytic leukemia: further regulation by CD55 and CD59.

Authors:  J Golay; M Lazzari; V Facchinetti; S Bernasconi; G Borleri; T Barbui; A Rambaldi; M Introna
Journal:  Blood       Date:  2001-12-01       Impact factor: 22.113

Review 2.  An integrated view of humoral innate immunity: pentraxins as a paradigm.

Authors:  Barbara Bottazzi; Andrea Doni; Cecilia Garlanda; Alberto Mantovani
Journal:  Annu Rev Immunol       Date:  2010       Impact factor: 28.527

3.  [Determination of alpha-amylase in microbial glucoamylase preparations].

Authors:  H Ruttloff; R Friese; M Richter
Journal:  Z Allg Mikrobiol       Date:  1970

Review 4.  Complement in cancer: untangling an intricate relationship.

Authors:  Edimara S Reis; Dimitrios C Mastellos; Daniel Ricklin; Alberto Mantovani; John D Lambris
Journal:  Nat Rev Immunol       Date:  2017-09-18       Impact factor: 53.106

5.  Malignant external otitis.

Authors:  D F Wilson; J L Pulec; F H Linthicum
Journal:  Arch Otolaryngol       Date:  1971-04

Review 6.  Inflammation and cancer: back to Virchow?

Authors:  F Balkwill; A Mantovani
Journal:  Lancet       Date:  2001-02-17       Impact factor: 79.321

Review 7.  Neutralizing tumor-promoting chronic inflammation: a magic bullet?

Authors:  Lisa M Coussens; Laurence Zitvogel; A Karolina Palucka
Journal:  Science       Date:  2013-01-18       Impact factor: 47.728

Review 8.  Cancer-related inflammation.

Authors:  Alberto Mantovani; Paola Allavena; Antonio Sica; Frances Balkwill
Journal:  Nature       Date:  2008-07-24       Impact factor: 49.962

Review 9.  The interaction of anticancer therapies with tumor-associated macrophages.

Authors:  Alberto Mantovani; Paola Allavena
Journal:  J Exp Med       Date:  2015-03-09       Impact factor: 14.307

Review 10.  Context-dependent roles of complement in cancer.

Authors:  Lubka T Roumenina; Marie V Daugan; Florent Petitprez; Catherine Sautès-Fridman; Wolf Herman Fridman
Journal:  Nat Rev Cancer       Date:  2019-10-30       Impact factor: 60.716

View more
  8 in total

1.  Neuregulin 4 suppresses NASH-HCC development by restraining tumor-prone liver microenvironment.

Authors:  Peng Zhang; Zhimin Chen; Henry Kuang; Tongyu Liu; Jiaqiang Zhu; Linkang Zhou; Qiuyu Wang; Xuelian Xiong; Ziyi Meng; Xiaoxue Qiu; Ramiah Jacks; Lu Liu; Siming Li; Carey N Lumeng; Qing Li; Xiang Zhou; Jiandie D Lin
Journal:  Cell Metab       Date:  2022-08-15       Impact factor: 31.373

Review 2.  The effects of radiation therapy on the macrophage response in cancer.

Authors:  Callum Beach; David MacLean; Dominika Majorova; James N Arnold; Monica M Olcina
Journal:  Front Oncol       Date:  2022-09-29       Impact factor: 5.738

3.  Complement C3a activates astrocytes to promote medulloblastoma progression through TNF-α.

Authors:  Biao Gong; Duancheng Guo; Chaonan Zheng; Zhen Ma; Jie Zhang; Yanghui Qu; Xinhua Li; Gen Li; Li Zhang; Yuan Wang
Journal:  J Neuroinflammation       Date:  2022-06-20       Impact factor: 9.587

Review 4.  Inside-Out of Complement in Cancer.

Authors:  Martin Kolev; Madhumita Das; Monica Gerber; Scott Baver; Pascal Deschatelets; Maciej M Markiewski
Journal:  Front Immunol       Date:  2022-07-01       Impact factor: 8.786

Review 5.  Evolution and Targeting of Myeloid Suppressor Cells in Cancer: A Translational Perspective.

Authors:  Augusto Bleve; Francesca Maria Consonni; Chiara Porta; Valentina Garlatti; Antonio Sica
Journal:  Cancers (Basel)       Date:  2022-01-20       Impact factor: 6.639

6.  A Complement-Related Gene Signature for Predicting Overall Survival and Immunotherapy Efficacy in Sarcoma Patients.

Authors:  Lin Zhang; Weihao Lin; Yang Zhou; Fei Shao; Yibo Gao; Jie He
Journal:  Front Cell Dev Biol       Date:  2022-04-14

Review 7.  Macrophages as tools and targets in cancer therapy.

Authors:  Alberto Mantovani; Paola Allavena; Federica Marchesi; Cecilia Garlanda
Journal:  Nat Rev Drug Discov       Date:  2022-08-16       Impact factor: 112.288

8.  Neutrophils activated by membrane attack complexes increase the permeability of melanoma blood vessels.

Authors:  Xiaobo Liu; Yuanyuan Wang; Alexander T Bauer; Michael Kirschfink; Peipei Ding; Christoffer Gebhardt; Lubor Borsig; Thomas Tüting; Thomas Renné; Karsten Häffner; Weiguo Hu; Stefan W Schneider; Christian Gorzelanny
Journal:  Proc Natl Acad Sci U S A       Date:  2022-08-12       Impact factor: 12.779

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.